Chris O'Donnell

TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company’s Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Our lead program TRB-061, currently in a Ph1 clinical trial for atopic dermatitis, is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California. For more info, visit www.trex.bio.

Building a smarter roadmap for precision therapeutics.

Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.

Our goal is to bring new therapy to cancer’s most frequently mutated oncogenic target. Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS. We rely on exceptional science, and our focus, always, is on patients.

Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. Petra Pharma will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohns disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas. Learn more at www.kymeratx.com

TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company’s Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Our lead program TRB-061, currently in a Ph1 clinical trial for atopic dermatitis, is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California. For more info, visit www.trex.bio.

Building a smarter roadmap for precision therapeutics.

Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.

We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines

Our goal is to bring new therapy to cancer’s most frequently mutated oncogenic target. Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS. We rely on exceptional science, and our focus, always, is on patients.